Analysts’ ratings for Ares Capital

Ares Capital’s (ARCC) analyst ratings have improved over the past few months due to rising earnings and originations. So far in February 2017, twelve of the 17 analysts covering the company have rated it as a “buy” or a “strong buy.” Five analysts rated it as a “hold.”

Since January 2017, Ares Capital’s ratings have improved, with its “strong buy” ratings rising from three to four. Its “hold” ratings have fallen from five to four. Analysts have given Ares Capital a one-year price target of $17.15, implying negative growth of 0.25%.

What Analyst Ratings Say about Ares Capital’s Performance

Ares Capital’s competitors

Among Ares Capital’s major closed-end peers, Prospect Capital (PSEC) saw two of eight analysts rate it a “buy” or “strong buy” in January 2017. Three analysts, or ~37.5%, rated it a “hold.” One analyst rated the company an “underperform, ” and two analysts rated it a “sell.” For BlackRock Capital Investment (BKCC), all five analysts covering the stock gave it a “hold.” For Apollo Investment (AINV), four of the 13 analysts covering the stock rated the company a “buy” or “strong buy,” nine analysts gave “hold” ratings, and two analysts gave “underperform” or “sell” ratings. Together, Ares Capital’s competitors make up 6.1% of the PowerShares Global Listed Private Equity ETF (PSP).

Latest articles

Apple (AAPL) investors have had a roller coaster week. Apple stock has lost just under 2% in a week, ending on August 23, 2019.

Competition taking a toll on Netflix as its share of US subscription video streaming market keep falling as rivals gain ground.

Crude oil production continues to rise, and oil prices remain at $50. Despite that, US energy stocks aren’t getting investors’ interest.

Apple stock fell 4.6% as the US-China trade war intensified today. China warned of tariffs on more US goods, followed by Trump's tweeted response.

In response to new tariffs from China and President Trump's tweets, the market tanked to session lows on Friday. The DJIA nosedived more than 600 points.

Coverage on Cresco Labs has increased from seven analysts in July to nine in August. Six analysts favor a “strong buy,” and three recommend a “buy.”